While Big Pharma chases billion-dollar blockbusters, a Brussels-based non-profit quietly orchestrates Europe’s most vital cancer trials. With 365 employees and a $46.5M budget, EORTC isn't a biotech—it's the invisible infrastructure of modern oncology.

"They don't sell drugs; they sell scientific certainty. EORTC is the neutral ground where competitors collaborate to cure cancer."

The traffic data tells a story of a captive audience. With 34% direct traffic and 52% organic, EORTC relies heavily on brand recognition and specific utility. Users aren't browsing; they are arriving with intent. Whether it's accessing the EORTC QLQ-PR25 questionnaire or looking up conference details, the site functions as a critical utility rather than a marketing funnel.

• Revenue is likely grant-driven and consortium-funded, not commercial sales.
• The 'RECIST 1.1' keyword dominance shows they own the terminology of cancer research.
• Social presence is broad but likely low-engagement—typical for academic institutions.
• Key personnel focus on data integrity and IT, signaling a data-first organization.